Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Much!!!! For the first time, Fosun Pharma made it into the Top50 of Asia's best listed companies
Category:
Trade info
Author:
Source:
Add time:2017-09-12 15:47
Summary:On August 24, the US "Forbes" biweekly published the list of the 50 best listed companies in Asia in 2017, including Fosun Pharma, Kangmei Pharmaceutical, Yunnan Baiyao, Huadong Medicine, and China Biopharmaceuticals and 5 Chinese pharmaceutical companies (China Biopharmaceuticals) Hong Kong, the registered place of pharmaceuticals, was on the list. Among them, Fosun Pharma made the list for the first time, ranking 33rd.
On August 24, the US "Forbes" biweekly published the list of the 50 best listed companies in Asia in 2017, including Fosun Pharma, Kangmei Pharmaceutical, Yunnan Baiyao, Huadong Medicine, and China Biopharmaceuticals and 5 Chinese pharmaceutical companies (China Biopharmaceuticals) Hong Kong, the registered place of pharmaceuticals, was on the list. Among them, Fosun Pharma made the list for the first time, ranking 33rd.
In the 2017 list of the 50 best listed companies in Asia released by Forbes this time, a total of 29 companies in mainland China were on the list, 22 companies were listed last year, and 25 companies were listed in 2015.
Forbes excluded companies with more than 50% state ownership from the 1,694 listed companies, and then conducted several rounds of elimination through revenue, revenue continuity, loss, debt ratio and other aspects, and finally came to this list. Forbes believes that these companies are the best blue chip stocks in Asia.
Among them, Forbes commented on Fosun Pharma that Fosun Pharma currently has mature pharmaceutical business and R&D business, hospital business and pharmaceutical chain retail store business, and long-term equity investment business. It holds 29.9% equity of Sinopharm, the largest pharmaceutical distribution company in China. .
Through continuous mergers and acquisitions, Fosun Pharma has firmly grasped a number of its own outstanding products in the fields of cardiovascular, anti-tumor, neurology, hematology, endocrine and digestive systems, and anti-infection treatment. In recent years, the domestic pharmaceutical innovation atmosphere has gradually increased, and Fosun Pharma has not dared to neglect its research and development, including the current hot Car-t immune cell therapy. Because of its cooperation with Kite Pharmaceuticals, it has successfully carried out an early layout.
Prior to this, Fosun Pharma had just won the "Top 100 Value Listed Companies on the Main Board of China's Listed Companies".
Founded in 1994, Fosun Pharma is a leading medical and health industry group in China. In the past ten years, Fosun Pharma Group's net profit index attributable to shareholders of listed companies after deducting non-recurring gains and losses has achieved a compound annual growth rate of approximately 36%. The company has distributed dividends for 17 consecutive years since its listing.
